 |
AIDS 2026: Adjusting to a Post-PEPFAR World
Health Policy Watch | July 30, 2026
|
|
AIDS 2026: Dolutegravir knocks down HIV faster than bictegravir
aidsmap | July 30, 2026
|
|
AIDS 2026: Long-Acting Weekly Oral HIV Therapy Advances Toward Regulatory Review
Infection Control Today | July 30, 2026
|
|
Long-Acting Weekly Oral HIV Therapy Advances Toward Regulatory Review
Infection Control Today | July 30, 2026
|
|
Dolutegravir knocks down HIV faster than bictegravir
aidsmap | July 30, 2026
|
|
AIDS 2026: Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting...
yahoo! | July 29, 2026
|
|
Monthly PrEP pill could be made for US$3 a year, but Latin America is shut out of generic licensing
aidsmap | July 29, 2026
|
|
Once-weekly oral tablet proves highly effective for HIV care
News Medical | July 29, 2026
|
|
Scientifically, lenacapavir PrEP takes a victory lap. But now worries about access
Managed Healthcare | July 28, 2026
|
|
MSF calls for key HIV prevention drug to be made affordable
yahoo! | July 26, 2026
|
|
Merck to let generic makers produce low-cost HIV prevention pill
TRTWorld | July 24, 2026
|
|
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
MERCK | July 24, 2026
|
|
Once Weekly Oral HIV Regimen Maintains Suppression Through Week 48
DrugTopics | July 22, 2026
|
|
In ongoing trials, twice-yearly HIV prevention drug saw just one case
devex | July 21, 2026
|
|
Investigational Once-weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who...
MERCK | July 21, 2026
|
|
Two- vs Three-Drug Combo for Immune Recovery in HIV Infection: No Clear Winner
Medscape | July 13, 2026
|
|
Lenacapavir offers extraordinary promise but communication will decide its impact
Daily Maverick | July 13, 2026
|
|
The cost of HIV drugs for Medicare is projected to skyrocket by 2035
CIDRAP | July 7, 2026
|
|
Doxycycline PEP Shows Limited Efficacy for Gonorrhea Prevention
IDA | July 6, 2026
|
|
New HIV vaccine successfully generates broadly neutralizing antibodies in primates
News-Medical | July 6, 2026
|
|
FDA Grants Priority Review for Dolutegravir in Newborns With HIV
Contagion Live | July 5, 2026
|
|
New HIV Drugs & What’s Coming Down the Pike
IDSE | July 3, 2026
|
|
What You Should Know About Idvynso for HIV
IDSE | June 30, 2026
|
|
FDA Approves Idvynso Combination Pill
POZ | June 29, 2026
|
|
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
Merck | June 29, 2026
|
|
National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers
AJMC | June 27, 2026
|
|
AIDSVu Releases 2025 PrEP Data Showing Record High PrEP Use, Though Persistent Gaps in HIV Prevention Access and Uptake Remain
AIDSVu | June 24, 2026
|
|
MSF at Pride: Gilead must increase global access to HIV prevention medicine
Doctors Without Borders | June 24, 2026
|
|
Few People With HIV on Medicare Are Using Long-Acting Treatment
POZ | June 24, 2026
|
|
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly...
Gilead | June 8, 2026
|
|
Switching or Simplifying Antiretroviral Therapy
National HIV Curriculum | Updated: June 3, 2026
|
| |
|
|
|
New HIV treatment could enable people to safely stop daily medication
Imperial.ac.uk | May 27, 2026
|
|
Ritonavir
HIV.gov | May 26, 2026
|
|
Antiretroviral Medications and Initial Therapy
National HIV Curriculum | Updated May 15, 2026
|
|
HIV PrEP Medications and Dosing Options
IDEA | May 15, 2026
|
|
Antiretroviral Medications and Initial Therapy
National HIV Curriculum | May 15, 2026
|
|
Inside the ‘miracle’ drug rollout that could end Aids
Independent | May 6, 2026
|
|
Clinical Guidance for PrEP
CDC | April 30, 2026
|
|
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
Gilead | April 29, 2026
|
|
State AIDS Drug Assistance Programs Linked to Higher HIV Viral Suppression Rates
IDA | April 28, 2026
|
|
Two-Drug, Single-Tablet Idvynso Receives FDA Approval for HIV-1
IDA | April 24, 2026
|
|
New study reveals few pharmacists prescribe “game-changer” HIV prevention drug
UC Berkeley | April 22, 2026
|
|
Monthly Islatravir Shows Comparable Safety for HIV PrEP, Lowers Lymphocyte Counts
IDA | April 6, 2026
|
|
Viral Suppression and an Undetectable Viral Load
HIV.gov | April 2, 2026
|
|
Existing medication could improve the health of people living with HIV
News Medical | March 23, 2026
|
|
What are the most important things to know about nevirapine?
HIV.gov | March 13, 2026
|
|
Bicillin® L-A Shortage
CDC | March 10, 2026
|
|
Long-acting medications transform HIV prevention, treatment
Healio | March 6, 2026
|
|
A Thorough Analysis of Changing Antibiotic Resistance in Dental Practice: A Narrative Review
Cureus | February 19, 2026
|
|
Drug Interactions with Antiretroviral Medications
National HIV Curriculum | February 12, 2026
|
|
What drugs are contained in the HIV treatment Symtuza?
Drugs.com | February 9, 2026
|
|
First of its kind daily HIV treatment shows promising results
Queen Mary University of London | February 9, 2026
|
|
Drug Database: Emtricitabine / Tenofovir Disoproxil Fumarate
HIV.gov | February 5, 2026
|
|
‘Transformative’ HIV PrEP shot slowly overcomes cost hurdles
The Hill | January 28, 2026
|
|
HIV persistence in tissues on dolutegravir-based therapy is not associated with resistance mutations to dolutegravir
Nature | January 27, 2026
|
|
PrEP
CMS.gov | January 20, 2026
|
|
Single-Tablet BIC/LEN Shows Good Results in Phase 3 for HIV Treatment
IDSE | January 16, 2026
|
|
New Once Weekly Investigational Oral Regimen Shows Strong 48 Week Results, Highlighting the Need for Easier HIV Treatment Options
UNC School of Medicine | January 16, 2026
|
|
Prior authorization and HIV medications: Considerations for state policymakers
hivma | January 16, 2026
|
|
Studies show that less frequent, all-injectable treatment for HIV is safe and preferred by adolescents
St Jude Children’s Research Hospital | January 15, 2026
|
|
PrEP Offers Everyone Protection From HIV
Cleveland Clinic | January 14, 2026
|
|
HIV infection Prevention in 2026: How PrEP Can Almost Eliminate Your HIV Risk
Doral Health & Wellness | January 13, 2026
|
|
Charity report urges government to commission PrEP through pharmacies
ThePhamaJournal | January 2, 2026
|
| |
|
|
